BioNews TexasUT Southwestern Researchers Determine Rituximab Safely Treated RA Patients …BioNews TexasRituximab, one of the first chimeric monoclonal antibody therapies, was developed in the mid 1990s for the treatment of disorders such as Hematologi…
|
Market Access Granted in France for Aggressive non-Hodgkin Lymphoma …
The Herald | HeraldOnline.com The European Medicines Agency’s (the EMA) Committee for Medicinal Products for Human Use has accepted PIX306, CTI’s ongoing randomized controlled Phase 3 clinical trial, which compares PIXUVRI-rituximab to gemcitabine-rituximab in patients who … CELL THERAPEUTICS INC : Market Access Granted in France for Aggressive …4-traders (press release) |
New Vasculitis Treatment As Good As Standard TherapyArthritis TodayFour weekly infusions of the biologic drug rituximab (Rituxan) work just as well to control a type of vasculitis as the current standard of care that involves 18 months of daily immunos…
Rituximab safely treated RA patients in long-term follow-upHealioThere were 3,194 patients (mean age, 51.5 years; 80.8% women) who had been treated with a maximum of 17 courses of rituximab plus methotrexate (MTX) for up to 9.5 years (all exposure pati…
|
Biosimilar Opportunities in an Evolving Market
KLFY In terms of revenue, six of the top ten pharmaceutical therapies are biological products, which have been targeted by biosimilar developers: Abbvie’s Humira (adalimumab), Roche’s MabThera (rituximab), Herceptin (trastuzumab) and Avastin (bevacizumab), … |
OncLiveIbrutinib Combo Achieves 100% Response Rate in Patients With NHLOncLiveAdding ibrutinib to standard rituximab (R)-CHOP chemotherapy for non-Hodgkin lymphoma (NHL) resulted in an objective response rate of 100%, according to the results of a smal…
|
Biosimilar Opportunities in an Evolving Market
Sacramento Bee In terms of revenue, six of the top ten pharmaceutical therapies are biological products, which have been targeted by biosimilar developers: Abbvie’s Humira (adalimumab), Roche’s MabThera (rituximab), Herceptin (trastuzumab) and Avastin (bevacizumab), … |
Epratuzumab and Rituximab Produce High Rate and Durable Progression-Free …NASDAQMORRIS PLAINS, N.J., Aug. 14, 2013 (GLOBE NEWSWIRE) –Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal ant…
MedscapeNew Scoring System Evaluates Prognosis in Burkitt LymphomaMedscapeAdding rituximab to chemotherapy has improved both response and survival rates, but that has been difficult to conclusively demonstrate in small, single-arm, single-institution s…
IMMUNOMEDICS, INC. : EPRATUZUMAB AND RITUXIMAB PRODUCE HIGH …4-traders (press release)based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced that the combination of epratuzumab and rituximab, as a …